Rafferty Asset Management
KROS icon

Rafferty Asset Management’s Keros Therapeutics KROS Stock Holding History

Rafferty Asset Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,280
Closed -$617K – 1108
2025
Q4 		$617K Sell
30,280
-13,786
-31% -$242K ﹤0.01% 880
2025
Q3 		$697K Sell
44,066
-10,228
-19% -$151K ﹤0.01% 851
2025
Q2 		$725K Sell
54,294
-1,038
-2% -$14K ﹤0.01% 812
2025
Q1 		$564K Buy
55,332
+9,531
+21% +$111K ﹤0.01% 840
2024
Q4 		$725K Buy
45,801
+4,689
+11% +$244K ﹤0.01% 850
2024
Q3 		$2.39M Sell
41,112
-16,443
-29% -$812K 0.01% 585
2024
Q2 		$2.63M Sell
57,555
-61,956
-52% -$3.33M 0.01% 568
2024
Q1 		$7.91M Buy
119,511
+54,230
+83% +$3.22M 0.03% 350
2023
Q4 		$2.6M Buy
65,281
+7,092
+12% +$222K 0.01% 607
2023
Q3 		$1.86M Sell
58,189
-12,067
-17% -$450K 0.01% 631
2023
Q2 		$2.82M Buy
70,256
+7,225
+11% +$317K 0.02% 547
2023
Q1 		$2.69M Sell
63,031
-2,785
-4% -$141K 0.02% 528
2022
Q4 		$3.16M Buy
65,816
+8,519
+15% +$398K 0.03% 473
2022
Q3 		$2.16M Buy
57,297
+19,936
+53% +$691K 0.02% 491
2022
Q2 		$1.03M Buy
37,361
+3,092
+9% +$136K 0.01% 629
2022
Q1 		$1.86M Sell
34,269
-2,536
-7% -$130K 0.01% 628
2021
Q4 		$2.15M Buy
36,805
+12,459
+51% +$621K 0.01% 633
2021
Q3 		$963K Sell
24,346
-1,000
-4% -$35.6K 0.01% 841
2021
Q2 		$1.08M Sell
25,346
-8,685
-26% -$470K 0.01% 861
2021
Q1 		$2.1M Buy
34,031
+30,951
+1,005% +$1.96M 0.01% 611
2020
Q4 		$217K Buy
+3,080
New +$194K ﹤0.01% 968

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Rafferty Asset Management's KROS Position: Q1 2026 in Review

Rafferty Asset Management sold out of Keros Therapeutics (KROS) in Q1 2026, closing a stake of 30,280 shares — an estimated $617K sold.

Rafferty Asset Management first reported a position in KROS in Q4 2020 and held it in 21 quarters. The position peaked at $7.91M in Q1 2024. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Rafferty Asset Management reported no remaining Keros Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 30,280 Keros Therapeutics shares in Q1 2026, an estimated $617K.
  • Rafferty Asset Management first reported a position in Keros Therapeutics in Q4 2020 and held it in 21 quarters.
  • Rafferty Asset Management's Keros Therapeutics position peaked at $7.91M in Q1 2024.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.